Latest revenue
$1.51B
as of 2026-03-31
Latest net income
$227.4M
as of 2026-03-31
Net margin
15.0%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $32.52B
- Enterprise value
- $32.52B
- P/E (trailing)
- 113.4×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $25.29
- 52-wk low
- $15.95
- Beta
- —
- Shares out
- 1.45B
5-year trend
What this company does
Item 1. Business Overview We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. In 2025, we generated total global revenue of approximately $5.3 billion, increasing revenue by approximately 40.2% from the prior year, while achieving net income of $286.9 million, net cash provided by operating activities of $1.1 billion and positive free cash flow of $941.7 million. We are serial innovators in hematology and have built a differentiated, wholly-owned, and foundational franchise. We are the only company with potentially best-in-class assets across three foundational chronic lymphocytic leukemia (“CLL”)…
AI summary unavailable — showing raw filing excerpt
Generated from BEIGF's filing dated 2026-02-26
Key risks
Table of Contents Item 1A. Risk Factors The following section includes material factors that we believe may adversely affect our business and operations. You should carefully consider the risks and uncertainties described below and all information contained in this Annual Report, including our financial statements and the related notes and “Part II-Item 7-Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding to invest in our ADSs, ordinary shares, or RMB Shares. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the…
AI summary unavailable — showing raw filing excerpt
Generated from BEIGF's filing dated 2026-02-26
Profitability
Gross margin
87.5%
3.6%Operating margin
8.4%
156.1%Net margin
5.4%
131.7%Return on equity
6.6%
134.0%Return on assets
3.5%
132.2%Leverage
Debt / equity
0.88×
13.0%Long-term debt / equity
0.22×
341.5%Debt / assets
46.7%
6.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $1.51B | +35.5% | $227.4M | +17802.1% | 15.0% |
Q4 2025 2025-12-31 | $1.50B | +32.8% | $66.5M | +143.8% | 4.4% |
Q3 2025 2025-09-30 | $1.41B | +41.0% | $124.8M | +202.9% | 8.8% |
Q2 2025 2025-06-30 | $1.32B | +41.6% | $94.3M | +178.3% | 7.2% |
Q1 2025 2025-03-31 | $1.12B | +48.6% | $1.3M | +100.5% | 0.1% |
Q4 2024 2024-12-31 | $1.13B | — | $-151.9M | — | -13.5% |
Q3 2024 2024-09-30 | $1.00B | +28.2% | $-121.3M | -156.3% | -12.1% |
Q2 2024 2024-06-30 | $929.2M | +56.1% | $-120.4M | +68.4% | -13.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on BEIGF — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$116.9M
Net activity
−$116.9M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns BEIGF
No institutional holdings on file for BEIGF yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once BEIGF's latest filing finishes processing.